Dutasteride 0.5 mg daily for 4 years in men 50-75 reduces the risk of detecting prostate cancer at biopsy and improves urinary symptoms related to a large prostate (Reduce trial)
In this study over 4 years, 6729 men between the ages of 50-75 with a PSA between 2.5-10 ng/mL and a negative prostate biopsy 6 months prior were randomized to receive dutasteride 0.5 mg daily or placebo and then undergo 10-core prostate biopsy at 2 and 4 years. The finding was that those taking dutasteride had a 23% risk reduction in detecting prostate cancer at biopsy. Dutasteride also helped men with urinary symptoms from an enlarged prostate, however sexual side effects occur. It also improves the sensitivity of the PSA test.